What is NeuroKaire?
NeuroKaire is at the forefront of transforming psychiatry and neurology through an innovative AI-enabled paradigm for precision medicine in Central Nervous System (CNS) diseases. The company's core technology involves differentiating patients' blood cells into neurons, offering a novel approach to diagnosis and treatment. This groundbreaking work positions NeuroKaire as a key player in the rapidly evolving field of neuro-therapeutics and precision healthcare.
How much funding has NeuroKaire raised?
NeuroKaire has raised a total of $10M across 1 funding round:
Other Financing Round
$10M
Other Financing Round (2024): $10M with participation from GreyBird Ventures, Meron Capital, and Jumpspeed Ventures
Key Investors in NeuroKaire
GreyBird Ventures
GreyBird Ventures is an investment firm focused on unique diagnostic technologies in the era of precision medicine, with a portfolio including NeuroKaire. They aim to assist investors in evaluating opportunities and understanding risks.
Meron Capital
Meron Capital focuses on investing in early-stage technology startups, providing them with capital, strategic expertise, and access to a valuable network.
Jumpspeed Ventures
Jumpspeed Investments is a venture capital fund focused on early-stage startups from the Jerusalem ecosystem, seeking innovative technology solutions that address significant market pains.
What's next for NeuroKaire?
The recent major strategic investment of $10M signals a pivotal growth phase for NeuroKaire. This capital infusion is expected to accelerate the company's research and development efforts, potentially enabling broader clinical trials and the scaling of its proprietary AI platform. The enterprise-level funding context suggests NeuroKaire is moving towards commercialization and market expansion, aiming to solidify its position as a leader in CNS precision medicine.
See full NeuroKaire company page
